1	The exception that proves the rule: Virulence gene expression at the onset of
2	Plasmodium falciparum blood stage infections
3	
4	Jan Stephan Wichers-Misterek ^{1,2,3} , Ralf Krumkamp ^{1,4} , Jana Held ^{5,6} , Heidrun von Thien ^{1,2,3} , Irene
5	Wittmann ⁷ , Yannick Daniel Höppner ^{1,2,3,4} , Julia M. Ruge ^{1,2,3,4} , Kara Moser ⁸ , Antoine Dara ⁸ , Jan Strauss ^{1,2,3,*} ,
6	Meral Esen ^{5,6,9} , Rolf Fendel ^{5,6} , Zita Sulyok ^{5,6,\$} , Peter G. Kremsner ^{5,6,10} , B. Kim Lee Sim ¹¹ , Stephen L.
7	Hoffman ¹¹ , Michael F. Duffy ¹² , Thomas D. Otto ¹³ , Tim-Wolf Gilberger ^{1,2,3} , Joana C. Silva ⁸ , Benjamin
8	Mordmüller ^{5,6,#} , Michaela Petter ^{7,12} , Anna Bachmann ^{1,2,3,4}
9	
10	¹ Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany
11	² Centre for Structural Systems Biology, Hamburg, Germany, Notkestraße 85, 22607 Hamburg, Germany
12	³ Biology Department, University of Hamburg, Hamburg, Germany
13	⁴ German Center for Infection Research (DZIF), partner site Hamburg-Borstel-Lübeck-Riems, Germany
14	⁵ Institute of Tropical Medicine, University of Tübingen, Wilhelmstraße 27, 72074 Tübingen, Germany
15	⁶ German Center for Infection Research (DZIF), partner site Tübingen, Germany
16	⁷ Institute of Microbiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Wasserturmstraße
17	3/5, 91054 Erlangen, Germany
18	⁸ Institute for Genome Sciences, University of Maryland, School of Medicine, 670 W. Baltimore St., Baltimore, MD 21201, USA
19	⁹ Cluster of Excellence: EXC 2124: Controlling Microbes to Fight Infection, Tübingen, Germany
20	¹⁰ Centre de Recherches Médicales de Lambaréné, BP242 Lambaréné, Gabon
21	¹¹ Sanaria Inc., 9800 Medical Center Drive, Rockville, MD 20850, USA
22	¹² University of Melbourne, Melbourne/Parkville VIC 3052, Australia
23	¹³ School of Infection & Immunity, University of Glasgow, Glasgow G12 8TA, UK
24	* present address: GEOMAR Helmholtz Centre for Ocean Research Kiel, 24105 Kiel, Germany
25	\$ present address: University Children's Hospital Tübingen, 72076 Tübingen, Germany
26	# present address: Radboud University Medical Center, Radboud Institute of Molecular Life Sciences, Department of Medical
27	Microbiology, Postbus 9101, 6500 HB Nijmegen, The Netherlands NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
28	Corresponding author: bachmann@bnitm.de

29

30 Abstract

31 Controlled human malaria infections (CHMI) are a valuable tool to study parasite gene expression in vivo 32 under defined conditions. In previous studies, virulence gene expression was analyzed in samples from 33 volunteers infected with the Plasmodium falciparum (Pf) NF54 isolate, which is of African origin. Here, 34 we provide an in-depth investigation of parasite virulence gene expression in malaria-naïve European 35 volunteers undergoing CHMI with the genetically distinct Pf 7G8 clone, originating in Brazil. Differential 36 expression of var genes, encoding major virulence factors of Pf, PfEMP1s, was assessed in ex vivo 37 parasite samples as well as in parasites from the in vitro cell bank culture that was used to generate the 38 sporozoites (SPZ) for CHMI (Sanaria[®] PfSPZ Challenge (7G8)). We report broad activation of mainly B-39 type subtelomeric located var genes at the onset of a 7G8 blood stage infection in naïve volunteers, 40 mirroring the NF54 expression study and suggesting that the expression of virulence-associated genes 41 is generally reset during transmission from the mosquito to the human host. However, in 7G8 parasites, 42 we additionally detected a continuously expressed single C-type variant, Pf7G8 040025600, that was 43 most highly expressed in both pre-mosquito cell bank and volunteer samples, suggesting that 7G8, 44 unlike NF54, maintains expression of some previously expressed var variants during transmission. This 45 suggests that in a new host, the parasite may preferentially express the variants that previously allowed 46 successful infection and transmission.

47

48 Introduction

49 Malaria caused by *Plasmodium falciparum* (Pf) remains one of the most serious global health problems, 50 especially among children under the age of five. The clinical symptoms of malaria are exclusively 51 associated with the erythrocytic stage of the parasite lifecycle, and virulence has been linked to the 52 variant surface antigen Pf erythrocyte membrane protein 1 (PfEMP1)¹. This immunodominant surface 53 antigen is encoded by approximately 60 different var genes that differ in the composition of their 54 adhesive extracellular protein domains, chromosomal location, and transcriptional orientation ²⁻⁴. 55 Group B var genes include the most telomeric genes on most of the 14 Pf chromosomes adjacent to

56 group A var genes. A few group B var genes are also present in central chromosomal clusters along with 57 group C var genes. The proteins encoded by group A are longer and more complex in domain 58 composition than those of the other var gene groups ⁵. Group A and B var genes, particularly those 59 containing an EPCR-binding CIDR α 1 domain, are more frequently associated with severe disease and complications in paediatric infections ⁶⁻¹¹. Group C var genes have been associated with mild malaria ¹², 60 61 and a single, highly conserved, subtelomeric, group E var gene encodes the VAR2CSA protein, which is 62 strongly associated with placental malaria ¹³. A few other variants (var1, var3) are also conserved in 63 various Pf isolates, but their biological function is still unknown. Although the total number of var genes 64 varies among Pf isolates, the proportion within each subgroup is relatively constant ⁵. Recently, 65 comparison of 15 genomes from geographically dispersed Pf isolates revealed that the highly 66 polymorphic variable gene families exhibit little sequence homology, some copy number variation, but 67 considerable consistency in their genomic organisation such as the orientation of the most telomeric 68 var gene, positional conservation, and a fairly consistent number of var genes in internal clusters with 69 similar orientation ¹⁴.

70 Var gene expression is monoallelic, i.e. each parasite expresses only a single variant at a given time ¹⁵. 71 Many factors have been found to contribute to the regulation of var gene expression, e.g., cis-acting 72 elements such as the var promoter and intron ^{16,17}, trans-factors ^{18,19}, higher order chromatin structures 73 ^{20,21}, and epigenetic marks ²²⁻²⁶. The majority of *var* genes is repressed in a heterochromatin 74 environment characterized by the histone modification histone 3 lysine 9 trimethylation (H3K9me3), 75 which is bound by heterochromatin protein 1 (HP1)²⁷⁻²⁹. The single active var gene is largely free of 76 H3K9me3 and instead assumes a euchromatic structure with promoter enrichment of the histone 77 variants H2A.Z and H2B.Z and histone acetylations including H3K9ac and H3K27ac ^{22,24,25,30}. 78 Nevertheless, a comprehensive mechanistic understanding of how the mutually exclusive regulation of 79 var expression occurs does not exist. Previous experiments examining switch rates in clonal cell lines 80 showed that subtelomeric var genes have higher switch rates than central var genes, with A-type var 81 genes rarely activated in *in vitro* cultures and so are not detected without selection pressure. 82 Mathematical modeling supports the idea of a non-random, highly structured switch pathway in which

an originally dominant transcript switches either to a new dominant transcript or back to the previous one via a set of switch intermediates ³¹. The *var2csa* gene of group E was previously proposed to be one such intermediate ^{32,33}. Therefore, switching of *var* gene expression is determined by intrinsic activation/deactivation rates of *var* genes, suggesting that the frequency of antigenic variation is a balanced process between hierarchical *var* switches and selective forces in the host, such as host genetics and immunity.

89 Controlled human malaria infections (CHMI) provide a tailored environment to study parasites var gene 90 expression in vivo under defined conditions, e.g., variables such as host immunity and infection time 91 (i.e., the number of replication cycles of the parasite) can be monitored or even controlled. Previous 92 results with the Pf isolate NF54 indicate that at some point during host-to-host transmission, the var 93 expression profile is reset, allowing a phenotypically diverse population of parasites expressing different 94 subtelomeric B-type var genes to enter the blood ^{34,35}. These results are consistent with observations in 95 a murine malaria model, in which mosquito transmission of serially blood-passaged parasites resulted 96 in broad activation of subtelomeric genes encoding variant surface antigens ³⁶. How this reset is 97 achieved at the molecular level is currently also unknown.

98 In the past, the NF54 isolate was commonly used for CHMI, but recently other strains have become 99 available for heterologous CHMI: 7G8 from Brazil, NF166.C8 from Guinea, and NF135.C10 from 100 Cambodia. All of these strains have been shown to be representative of their geographic origin and to 101 differ in their genome structure, sequence, and immunogenic potential ^{37,38}. The NF54 isolate was 102 isolated from a Dutch patient who lived near Schiphol Airport, Amsterdam, and had never left the 103 Netherlands. The infected mosquito responsible for this airport malaria case was probably imported 104 from Africa³⁹. In contrast, 7G8 was cloned from the IMTM22 isolate in 1984 and selected for its ability 105 to produce microgametes, exflagellate, and infect Anopheles freeborni resulting in oocysts and 106 sporozoites ⁴⁰.

107 In the present study we show the first *in vivo* data on *var* gene expression from CHMI with malaria-naïve 108 volunteers infected with the Pf clone 7G8 and provide new insights into the *var* gene expression pattern 109 that Pf uses to establish a blood stage infection after transmission from one human host to another.

- 110
- 111 Results
- 112

113 The 7G8 var gene repertoire and the domain composition of the encoded PfEMP1 variants

114 In total, the 44 var genes of the 7G8 clone longer than 6 kb were analyzed in this study (Table S1). An 115 additional 24 short var gene pseudogenes and fragments are annotated in PlasmoDB Release 58 (23. 116 June 2022) ⁴¹. To account for this, we also included a single C-type pseudogene (Pf7G8 120024200)

117 (Table S1) ¹⁴.

118 The Pf clone 7G8 encodes six group A var genes, including two var1 variants (IT- and 3D7-type ⁴²), 28 119 group B var genes, ten group C var genes (including the Pf7G8 120024200 pseudogene) and one group 120 E var2csa gene (Table S1, Figure 1A)^{14,37}. Genes of the conserved var3 subfamily are absent. Two var A 121 genes encode CIDR α 1 domains that presumably can bind EPCR, and the other two A-type variants have 122 a N-terminal head structure with CIDR δ/γ domains of unknown binding capacity. All remaining B- and C-type var genes encode PfEMP1 with CIDRa2-6 domains responsible for binding the host's CD36 123 124 receptor. In total, 24 genes of type A, B or E are located in subtelomeric regions (24/44=54.6%), although 125 it is unclear on which chromosome the var gene Pf7G8 000005200 is located. Three pseudogene 126 annotations larger than 6 kB can be found on PlasmoDB: the var1 copy (3D7-type), the group E var2csa 127 gene and the B-type gene Pf7G8 060005400. All contain a premature stop codon in the ATS sequence 128 (Table S1).

129

130 In vitro var transcript profiles of cell bank 7G8 parasites at ring stage prior to mosquito passage

131 Based on the newly assembled and annotated 7G8 var gene set, we designed and validated gene-132 specific primer pairs for each var gene (Table S2). Subsequent qPCR and RNA-seq analysis was 133 performed side-by-side using RNA from ring-stage parasites prior to mosquito infection (Sanaria cell 134 bank, aliquot B, generation 13). The Bland-Altman-Plot of the expression values shows high similarity 135 between the two data sets with only three outliers, Pf7G8 020026900 (A, var1-IT), Pf7G8 050037900 136 (A, var1-3D7) and Pf7G8 060022500 (B-type) (Figure 1B–D).

137 In addition, we performed comparative qPCR analysis of two cell bank aliquots A and B to probe into 138 putative variations within the parasite population used for sporozoite production. We showed that the 139 var gene expression pattern in both aliquots is dominated by a centromeric group C var gene variant, 140 Pf7G8_040025600, which accounts for 30.3% (aliquot A, generation +12 after thawing) and 43.3% 141 (aliquot B, generation +6 after thawing) of the total var gene transcripts, followed by a second 142 centromeric type C var gene, Pf7G8_080014200 (aliquot A: 25.2%; aliquot B: 14.9%), and the group E 143 var2csa gene, Pf7G8 120005700 (aliquot A: 10.8%; aliquot B: 4.5 %) (Figure 2A, B, Table S3). This 144 specific expression pattern was revalidated in both cell bank aliquots after additional in vitro 145 proliferation cycles (aliguot A: +15, +24; aliguot B: +13, +19). It was found that the overall pattern of var 146 gene expression among each aliquot remained similar over time, though Pf7G8 040025600 expression 147 declined in aliquot A at the last time point (Figure 2A, Table S3).

148

149 In vivo var transcript profiles in malaria-naïve volunteers infected with 7G8 sporozoites

150 Next, we analyzed the var gene expression profiles in samples from 7G8-infected volunteers from two 151 different clinical trials, MAVACHE ⁴³ and CVac-Tü3 ⁴⁴ (Figure S1). Our analysis of var gene expression 152 profiles in parasites from eleven individual malaria-naïve volunteers (Table 1) showed that transcripts 153 of all 45 var gene variants were detectable during the early blood stage 7G8 infection, similar to the 154 expression pattern previously observed in NF54³⁵. Interestingly, all volunteer samples showed a very 155 similar var gene expression pattern (Figure 2A, C, D, E) dominated by the same single centromeric group 156 C var gene variant, Pf7G8_040025600, accounting for a median 41.0% (IQR: 37.7–49.4) of total var gene 157 expression (Table S3). In addition, a broad induction of subtelomeric var genes, mainly group B, was 158 observed (Figure 2A, C, D). Besides the dominant Pf7G8 040025600, the next ten most highly expressed 159 var variants, each accounting for more than 2% of total var gene expression, are classified as B-type, 160 and nine of them are located in subtelomeric regions (Figure S2, Table S3). Hierarchical cluster analysis 161 and pairwise Pearson correlation coefficients of samples from pre-mosquito cell bank parasites and 162 malaria-naïve infected volunteers showed clearly distinct expression profiles except for the dominant 163 C-type Pf7G8_040025600 highly expressed in both (Figure 2A, E). Consistent with this, a comparison of

expression levels between subtelomerically located *var* genes in parasites from malaria-naïve volunteers and pre-mosquito cell bank parasites revealed a significant difference between both gene subsets, while a comparison of only centromeric *var* gene expression revealed no significant difference (Figure 2F). In general, significantly higher expression of subtelomerically located genes compared to centromeric genes was observed *in vivo*.

169

170 Characterization of dominant C-type *var* gene expressing parasites

171 All 11 samples from 7G8-infected volunteers analyzed in this study had the same var expression 172 signature: The C-type var gene Pf7G8_040025600 was the dominant transcript that did not appear to 173 be reset during transmission. This might suggest that this gene in 7G8 is mis-regulated in a way that it 174 is either i) permanently activated, or ii) escapes from the mutually exclusive epigenetic silencing 175 machinery, or iii) not subject to resetting during transmission ^{34,35}. Pf7G8 040025600 is the only var 176 gene present in a central cluster of variant surface antigen genes on chromosome 4, where most other Pf strains have multiple var genes ¹⁴, and which also includes a ruf6 sequence, a rif gene, and a var 177 178 pseudogene. To probe into the first hypothesis, we re-evaluated the RNA-seq transcriptome data from 179 the pre-mosquito cell bank parasites (aliquot B) but found no apparent activation of the other genes 180 near Pf7G8_040025600. Some smaller non-coding transcripts were expressed at low level from 181 upstream of this locus, including a *ruf6* sequence known to positively regulate neighboring var genes⁴⁵ 182 (Figure 3A).

Second, to ensure that Pf7G8_040025600 expression did not exhibit an aberrant expression profile during asexual blood stage development, we tightly synchronized 7G8 parasites from the cell bank and performed qPCR on ring and schizont stage parasites. The data showed that Pf7G8_040025600 expression, as well as expression of all other minor *var* transcripts, was downregulated upon parasite maturation, as expected: Schizonts showed a 22-fold reduction in relative expression compared to ring stage parasites (relative expression values of 36,357.1 in rings and 1,659.1 in schizonts) (Figure 3B). Third, to test if Pf7G8_040025600 escaped mutually exclusive expression, we panned pre-mosquito cell

189 Third, to test if Pf7G8_040025600 escaped mutually exclusive expression, we panned pre-mosquito cell

190 bank parasites (aliquot A) on recombinant CSA, allowing selection of parasites expressing the CSA-

191 binding PfEMP1 variant encoded by the *var2csa* gene ⁴⁶. In parallel, an aliquot of 7G8 parasites obtained 192 from BEI Resources (MRA-152) was subjected to the same procedure as a control for CSA binding. 193 Immediately prior to selection on CSA, the pre-mosquito cell bank parasites expressed 194 Pf7G8_040025600 (48.7%), Pf7G8_080014200 (17.5%) and the var2csa Pf7G8_120005700 at a much 195 lower level (7.0%). In 7G8 MRA-152 parasites, the var2csa gene Pf7G8 120005700 clearly dominated 196 the expression pattern even without any selection on CSA (96.2%), which was also the case in the two 197 other 7G8 lines deposited at BEI Resources by different providers (MRA-154: 97.9%; MRA-926: 74.6%) 198 (Figure S3). After three rounds of selection, both 7G8 lines expressed the var2csa gene 199 Pf7G8 120005700 almost exclusively (cell bank aliquot A: 99.2%; MRA-152: 98.9%) (Figure 3C, D; Table 200 S4). The conserved *var2csa* gene is known to encode the ligand for CSA 46 , although it was annotated as 201 a protein-coding pseudogene in 7G8 on PlasmoDB Release 58 (23. June 2022) due to a premature stop 202 codon at position 8,622 bp resulting in a truncated ATS sequence lacking the terminal 220 amino acids 203 (Table S1). However, in agreement with recent reports, our data suggest that the 7G8 var2csa gene 204 encodes a fully functional protein that is exported to the host cell surface and can bind CSA in vitro ^{47,48}. 205 Fourth, another explanation for the high expression of the C-type gene Pf7G8_040025600 in pre-206 mosquito cell bank parasites as well as in parasites infecting the volunteers could be a very strong 207 promoter or preference of the 7G8 strain used for CHMI to switch to Pf7G8_040025600 expression. 208 This was investigated by cultivating the CSA-selected cell bank parasite aliquot A for an additional 100 209 parasite replication cycles. At every 10th parasite generation, the var gene expression pattern was 210 analyzed by qPCR, which was surprisingly stable over time with almost exclusive expression of the 211 var2csa gene (Figure S4, Table S4). The expression of Pf7G8_040025600 was rather low, with a median 212 relative expression value of 189.3 (IQR: 61.1–303.1) compared to the median var2csa expression value 213 of 357,486.3 (IQR: 260,004.0–563,871.6). These data indicate that predominant or frequent switching 214 to Pf7G8_040025600 expression in the 7G8 strain used is unlikely to be a major factor in upregulated 215 expression of this gene in pre- and post-mosquito samples.

216 So far, all these data supported normal regulation of the Pf7G8_040025600 gene. However, because 217 analyses at the parasite population level could miss individual variations in single parasite clones, we

218 produced 13 clones from the cell bank aliquot A after 36 in vitro replication cycles by limiting dilution. 219 The expression pattern of var genes was determined by qPCR, and eight clones were selected for further 220 comparison: five of the clonal cell lines showed distinct expression of Pf7G8 040025600 (A1E4, A1G5, 221 A2E10, A2F10, A2G2), while three cell lines dominantly expressing other var genes of type C (A1F4: 222 Pf7G8 120024200, A1F11: Pf7G8 080014200) or E (A1G9: Pf7G8 120005700/var2csa) were chosen as 223 controls (Figure 3C, D). These var expression patterns further confirm that the mechanism of mutually 224 exclusive expression regulation in Pf7G8 040025600-expressing cell lines is still intact. Moreover, the 225 successful selection of subclones for CSA binding revealed that var gene expression is not permanently 226 fixed to this variant but can still switch to var2csa, which was confirmed at the RNA and protein levels 227 (Figure 3C, D). The presence of all var genes on gDNA level in each subclone was verified by qPCR (Figure 228 S5).

229 To identify genomic alterations in 7G8 cell bank subclones possibly associated with persistent 230 expression of Pf7G8 040025600 after transmission, the subclones A2E10, A2G2 (both expressing 231 Pf7G8 040025600), and A1G9 (control) were subjected to whole genome sequencing. After stringent 232 filtering, both Pf7G8_040025600-expressing clones had mutations of A to G at position 886709 on 233 chromosome 11, which is located in the intron of the ERO1-encoding gene Pf7G8_110027600 (putative 234 endoplasmic reticulum oxidoreductin), and at position 679487 on chromosome 12 within the coding 235 region of gene Pf7G8 120022100 (putative sno-RNA-associated small subunit rRNA processing protein), 236 reflecting a synonymous exchange. Clone A2G2 had two additional single nucleotide mutations on 237 chromosome 10 at positions 1015567 (C->T, nonsynonymous) and 1015545 (T->C, synonymous), both 238 within Pf7G8 100029900, which encodes a conserved membrane protein of unknown function. Overall, 239 whole genome sequencing revealed no nonsynonymous changes between the subclones expressing the 240 Pf7G8 040025600 gene and the *var2csa*-expressing control (Table S5), making it unlikely that genetic 241 differences between the two subpopulations cause reset failure.

Finally, to exclude epigenetic differences in gene regulation, we also performed ChIP-qPCR using ring stages from the cell bank aliquot A (bulk culture) and the same parasite line enriched for CSA-binding, as well as the cell bank subclones A2E10 (expressing Pf7G8_040025600) and A1G9 (*var2csa*-expressing

245 control) (Figure 4, Table S6). Several epigenetic marks typically involved in var gene regulation were 246 inspected, including the heterochromatin mark H3K9me3, which is associated with silent var genes ²², 247 the euchromatic mark H3K27ac, which is typically enriched in active var promoters ³⁰, and the histone 248 variant H2A.Z, which occupies active var promoters as well as var introns regardless of expression status 249 ²⁴. Both, the CSA-enriched cell bank culture and the A1G9 subclone showed the expected epigenetic 250 profile at their expressed var2csa-loci (low H3K9me3, high H3K27ac/H2A.Z) and the silenced 251 Pf7G8 040025600 locus (high H3K9me3, low H3K27ac/H2A.Z). However, this was less obvious in 252 unselected cell bank parasites as well as the A2E10 subclone with dominant Pf7G8_040025600 253 expression. The Pf7G8 040025600 gene was clearly heterochromatic at a similar level as the var2csa 254 gene, and was only marginally enriched for activation marks at the promoter (H2A.Z, H3K27ac) (Figure 255 4B, C). However, at least a slight reduction of H3K9me3 in Pf7G8 040025600 expressing relative to 256 var2csa expressing cultures was consistently observed at the Pf7G8 040025600 gene, indicating that 257 the locus may be partially unpacked from heterochromatin in part of the population. Parallel RNA 258 analysis revealed that selection of parasites on CSA indeed resulted in a homogenous population with 259 very high var2csa expression, whereas the unselected cell bank parasites and the A2E10 subclone 260 showed a more diverse pattern of var expression with lower levels of total var expression and 261 Pf7G8_040025600 in particular, which may possibly explain the differences in signal intensity of the 262 epigenetic marks (Figure 4D).

263 Overall, we demonstrated that expression of the C-type gene Pf7G8_040025600 (i) is a unique feature 264 of parasites from the Sanaria cell bank, (ii) is correctly regulated across asexual blood stages, (iii) occurs 265 in a mutually exclusive manner, and (iv) parasites are neither fixed to nor tend to preferentially activate 266 expression of this variant after selection for var2csa expression. Moreover, parasites expressing this var 267 variant share the genomic and epigenetic background with parasites expressing other var variants, 268 which further rules out the presence of two distinct 7G8 parasite populations in the original cell bank 269 aliquots, with one population behaving like NF54 and resetting var gene expression during mosquito 270 passage, and the other population having lost its ability to reset var expression and being fixed to 271 express Pf7G8_040025600. Therefore, our data rather support the second hypothesis, namely that

Pf7G8_040025600 is not subject to resetting during transmission, suggesting that epigenetic resetting
of *var* genes can be incomplete during passage through mosquitoes, possibly through the
semiconservative retention of histone modifications at replicated *var* loci during meiosis.

275

276 Discussion

277 After transmission, parasites are faced with a new environment defined by various parameters such as 278 the metabolic state of the host, pre-existing immunity, drug pressure, pregnancy or other infections. 279 One way to cope with these alterations might be to epigenetically reset genes upon transmission to 280 create a diverse population of parasites expressing different var genes from which clones best adapted 281 to the new environment can expand. This "bet-hedging" strategy, which is a viable alternative to 282 directed transcriptional responses, is thought to be key to adaptations to general variations in the 283 environment ⁴⁹. This has been shown, for example, for expression of *var* genes after liver release of 284 NF54 parasites in CHMI of immunologically naïve individuals ^{34,35,50,51}. There, expression of var genes at 285 the onset of infection shows a broad activation pattern of many group B subtelomeric genes and certain 286 group A variants. This broad expression repertoire is reduced in NF54 parasites from infected volunteers 287 with a higher degree of pre-existing immunity. In these individuals, only a single or very few var gene 288 variants are highly expressed, presumably encoding PfEMP1 which are not recognized by the host 289 immune system ³³. Intriguingly, the var gene expression profile changed dramatically during mosquito 290 passage of NF54 Pf parasites from the monoallelic var2csa expression in the initial culture used for 291 gametocytogenesis and sporozoite production to the broad pattern of subtelomeric var gene 292 transcription in the infected volunteers ^{35,51,52}.

In this study, we investigated whether the observations using NF54 parasites also hold true in other Pf isolates, or whether parasite strain-specific differences in *var* gene expression patterns can be observed. This is of particular importance because current vaccination concepts using whole parasites – either radiation-attenuated sporozoites (PfSPZ Vaccine) or sporozoites co-administered with chemoprophylaxis (PfSPZ-CVac) – are based on the strain NF54. For the first time, we have obtained expression data for the entire *var* gene repertoire in another parasite strain, 7G8, which originates from

299 a different geographic region and is genetically distinct from NF54 ^{37,38}. When 7G8 parasites were used 300 for CHMI, a very similar pattern of var gene group B activation was observed in naïve volunteers. This 301 suggests that Pf generally preferentially activates subtelomeric var genes after release from the liver, 302 while central var genes tend to remain silent ³⁵, allowing a phenotypically diverse population of parasites 303 expressing different subtelomeric var genes to enter the blood from the liver. These results are 304 consistent with observations in a mouse malaria model, where transmission of serially blood-passaged 305 parasites by mosquitoes resulted in broad activation of subtelomeric genes encoding variant surface 306 antigens ³⁶. How this switch occurs at the molecular level is currently unknown, but there is strong 307 evidence that the regulation of var genes in Pf relies on epigenetic mechanisms ⁵²⁻⁵⁴.

308 The broad activation pattern of many var genes seems to contradict the concept of safeguarding the 309 antigenic repertoire. However, this strategy of releasing a parasite population from the liver that 310 expresses PfEMP1 proteins with diverse adhesive properties would allow optimal and rapid adaptation 311 to a new host environment shaped by selective forces such as host genetics and pre-existing immunity. 312 At the same time, maintaining a repertoire of var gene variants silenced after liver release would 313 prevent the parasites from exposing their entire antigenic repertoire too early. Differences in intrinsic 314 switching rates of individual var genes would then lead to the expansion of parasite populations that 315 express dominant PfEMP1 variants during the course of infection and are further selected by immunity, 316 consistent with the fashion observed in chronic infections.

317 Interestingly, the dominant C-type var gene Pf7G8_040025600 in our study escapes from resetting 318 during transmission. There are at least five possible explanations for the high expression of this variant 319 in pre-mosquito parasites and in vivo during infection of volunteers: (i) the gene might have escaped 320 mutually exclusive expression, (ii) Pf7G8 040025600 might be generally deregulated during asexual 321 blood stage development, (iii) a subpopulation of parasites might have a mutation or carry epigenetic 322 marks making this variant resistant to the resetting mechanism during mosquito passage, (iv) this var 323 gene variant could have a very active promoter that allows high expression levels under different 324 conditions, or (v) only parasites expressing var2csa or other var gene variants that act as switching hubs 325 are able to reset their var gene expression during transmission. We tested most of these hypotheses

326 and demonstrated that Pf7G8 040025600 expression is mutually exclusive with that of other var genes, 327 and the gene is correctly repressed in schizonts, does not have a higher on switch rate than other var 328 gene variants, and none of the few genetic differences observed between clonal Pf7G8 040025600-329 and var2csa-expressing parasites can explain the phenotype. Moreover, these parasites were still able 330 to switch their var expression to a different variant, consistent with the successful generation of 7G8 331 sporozoites by Sanaria, suggesting that the switch from asexual replication to gametocytogenesis is also 332 not hindered in these parasites. Our results from ChIP-qPCR also suggest that epigenetic regulation of 333 Pf7G8_040025600 is not affected, as the gene is normally silenced by heterochromatin. The absence of 334 detection of activating histone marks may be explained by the mixed var expression pattern in about 335 half of the population, as it is known that in parasite populations with heterogeneous var gene 336 expression, signals from ChIP-qPCR or -seq can be leveled out ^{51,55}.

337 Based on our data, we hypothesize that var gene expression may partly underlie epigenetic imprinting 338 during transmission from one human host to another, which is thought to depend on the ability of each 339 var gene locus to establish and maintain heterochromatin. Consistent with other studies showing that 340 C-type var genes are turned on less frequently but can dominate expression patterns by slow silencing 341 ^{56,57}, C-type var genes may be less effective at re-establishing heterochromatin during transmission, in 342 line with their location in central chromosomal regions with likely fewer Sir2A-dependent silencing 343 nucleation sequences. In conjunction with the intrinsic promoter activity of each var gene variant, Pf 344 could exhibit a loose activation hierarchy of subtelomeric var genes upon entry into the human blood 345 phase. This strategy would allow the parasite population to explore a new host environment by 346 expressing many different PfEMP1 variants as well as testing the previously successful variant in a 347 different host, adding another layer to the parasite's survival or adaptive strategies in humans. Although 348 purely speculative, this could also explain why some parasite strains cause more severe disease courses 349 than others. However, since var2csa is also discussed as a switching intermediate ³¹⁻³³, it is possible that 350 resetting is also coordinated via intermediate var2csa expression, from which parasites can express var 351 genes at the onset of the blood phase with probabilities based on intrinsic on-rates for each variant. It 352 should be noted that truncation of VAR2CSA-ATS in 7G8 parasites could also affect the efficiency of

353 these processes. Further studies, such as CHMIs with NF54 parasites or other strains expressing 354 different *var* gene variants prior to transmission, or with parasites with genetically modified *var2csa* 355 locus, are needed to evaluate these hypotheses.

356 In summary, we demonstrated that (i) expression of subtelomeric B-type var genes is induced in 7G8 357 parasites at the onset of blood stage infection in malaria-naïve individuals, (ii) cell bank parasites used 358 for PfSPZ production and isolated from volunteers exhibit an expression pattern dominated by a single 359 C-type variant, Pf7G8_040025600, suggesting that this C-type variant underlies epigenetic memory 360 during mosquito passage. Our results from two genetically distant parasite backgrounds show that 361 expression of virulence-associated genes in Pf is, at least partially, reset to subtelomeric B-type 362 expression during transmission from mosquito to human host, but also provide evidence for an 363 alternative strategy of the parasite in which infection in the next host is established by maintenance of 364 expression of a previously successful PfEMP1 variant in part of the parasite population. This suggests 365 that the PfEMP1 variant expressed in the previous malaria patient is an important factor that could 366 determine the pathophysiology of the subsequent infection. In conclusion, the NF54 strain and its clone 367 3D7 appear to be an accurate reference for the entire species in terms of gene content and organization, 368 as previously noted by Otto et al.¹⁴, but there appear to be differences among Pf isolates in resetting 369 var gene expression during transmission to establish infection in another human host ^{34,35}.

370

371 Methods

372

373 Ethics

The ethics committee of the University Clinic and the Medical Faculty of the University of Tübingen approved both studies, MAVACHE and CVac-Tü3, of which samples were examines in this work, and the U.S. Food and Drug Administration Agency (FDA) provided regulatory oversight. The studies were conducted according to the principles of the Declaration of Helsinki in its 6th revision and the guidelines of the International Conference on Harmonization–Good Clinical Practice (ICH-GCP). For the MAVACHE

study, the registration code at ClinicalTrials.gov is NCT02704533; the CVac-Tü3 trial is registered with
the EU Clinical Trial Register under 2018-004523-36. All volunteers provided written informed consent,
and understanding of the study and procedures was assessed with a quiz.

382

383 CHMI trials and blood sampling

384 Samples were collected during different phases of the MAVACHE ⁴³ and CVac-Tü3 trials ⁴⁴. Both trials 385 were conducted at the Institute of Tropical Medicine in Tübingen, Germany, where healthy, malaria-386 naïve volunteers were infected with live, infectious, aseptic, purified, cryopreserved NF54 or 7G8 387 sporozoites (Sanaria® PfSPZ Challenge (NF54) and Sanaria® PfSPZ Challenge (7G8)) manufactured by 388 Sanaria Inc., USA, 7G8 under license from Walter Reed Army Institute of Research. On the day of 389 treatment, up to 50 mL of blood was taken from all volunteers into sodium citrate tubes and processed 390 by Ficoll gradient centrifugation followed by filtration of the washed red blood cell pellet through a 391 Plasmodipur filter (EuroProxima).

392 The MAVACHE trial aimed to sequentially optimize the dose and schedule of PfSPZ Vaccine, verified by 393 randomized, controlled, double-blind immunization and controlled human malaria infection in malaria-394 naïve, healthy adult volunteers in Germany. The dose optimization phase included a dose-finding phase 395 to evaluate the safety, tolerability and infectivity of 7G8 PfSPZ in malaria-naïve, healthy adult volunteers. 396 A total of nine volunteers received either 800 (n=3), 1,600 (n=3) or 3,200 (n=3) 7G8 PfSPZ. Similar to 397 NF54, 7G8 PfSPZ at a dose of 3,200 PfSPZ resulted in parasitemia in 3/3 of the volunteers, and 2/3 398 volunteers developed parasitemia after infection with 800 and 1,600 PfSPZ, respectively, all 399 administered by direct venous inoculation. Parasite kinetics and clinical presentation are similar to CHMI 400 with NF54 PfSPZ⁵⁸. Samples from five volunteers are included in our study (800 PfSPZ: M08.1D, M08.2D; 401 1,600 PfSPZ: M16.1D; 3,200 PfSPZ: M32.1D, M32.2D) (Table 1, Figure S1). During the regimen 402 verification phase, volunteers were either infected with PfSPZ Vaccine or received placebo, followed by 403 a CHMI three weeks after the last immunization. The placebo group received normal saline instead of 404 PfSPZ Vaccine, but also underwent subsequent CHMI. Samples from three volunteers infected with 7G8 405 PfSPZ (M32.3P, M32.4P, M32.5P) were included in our study (Table 1, Figure S1).

The CVac-Tü3 trial assessed the safety and protective efficacy of a simplified Pf sporozoite
Chemoprophylaxis Vaccine (PfSPZ-CVac) regimen in healthy malaria-naïve adults in Germany ⁴⁴. In total,
NF54 PfSPZ of PfSPZ-CVac was administered three times (day 0, 5 and 28) to volunteers receiving parallel
chloroquine treatment (1.1 x 10⁵ PfSPZ each), and these volunteers underwent CHMI with 3,200 7G8
PfSPZ ten weeks after the last immunization. Samples from three placebo-infected volunteers (C32.1P,
C32.2P, C32.3P) could be included into our study (Table 1, Figure S1).
In total, samples from eleven malaria-naïve volunteers infected with 7G8 PfSPZ were included in this

413 study.

414

415 Parasite cell culture

416 7G8-MRA-152 (contributed by David Walliker), 7G8-MRA-154 (contributed by Dennis E. Kyle) and 7G8-417 MRA-926 (contributed by Karen Hayton and Tom Wellems) parasites were obtained through BEI 418 Resources, NIAID, NIH. Two frozen vials (termed cell bank aliquots A and B) of 7G8 parasites from 419 Sanaria's working cell bank (lot: SAN03-021214 from 20. February 2014) were separately thawed and 420 cultured in human O+ erythrocytes and in presence of 10% heat-inactivated human serum in parasite 421 culture medium according to standard procedures ⁵⁹. To maintain synchronized parasites, 7G8 cultures 422 were treated either with 5% sorbitol⁶⁰. Tight synchronization was performed by percoll-enrichment of 423 schizont ⁶¹ followed by sorbitol treatment after 4 hours of cultivation. From cell bank aliquot A ring stage 424 parasites were collected at generations 12, 15 and 24 after thawing, from cell bank aliquot B at 425 generations 6, 13 and 19.

426 Selection of *var2csa* expressing parasites was performed by panning on plastic dishes coated with 50
 427 μg/ml bovine trachea CSA (Sigma), as described previously ⁶². Subclones of Pf7G8 cell bank aliquot A
 428 were generated by limiting dilution cloning, as described previously ⁶³.

429

430 Western blot analysis

 $431 \qquad \text{Trophozoite stage cultures were treated with 0.075\% saponin in PBS to release hemoglobin from the}$

432 erythrocytes. Parasites and membrane ghosts were pelleted by centrifugation, washed three times in

433 PBS containing protease inhibitors (cOmplete EDTA free, Roche), and extracted in 2 x Laemmli buffer. 434 The protein extracts were separated on 3-8% Tris-Acetate gels (Invitrogen) and transferred to 435 nitrocellulose membranes (Millipore). The blots were probed with monoclonal mouse anti-ATS (6HI) 436 antibody ⁶⁴ or rabbit anti-*Plasmodium* aldolase antibody (abcam, ab207494) as loading control. 437 438 gDNA purification for whole genome sequencing 439 For gDNA sequencing, 150 mL Pf cell culture with >10% parasitemia were harvested for the 7G8 cell 440 bank aliquot A subclones A1G9, A2E10, and A2G2 and gDNA isolation was performed using the 441 MasterPure[™] Complete DNA purification kit (Lucigen) according to the manufacturer's instructions "Cell

samples" followed by "Complete Removal of RNA" with additional RNase I treatment. The gDNA samples

 $443 \qquad \text{were checked for degradation and RNA contamination on an agarose gel and quantified with the Qubit^{\texttt{M}}}$

444 dsDNA BR Assay Kit (ThermoFischer).

445

446 RNA purification and cDNA synthesis

Red blood cells were settled by centrifugation and completely lysed in 5 volumes of pre-warmed TRIzol (ThermoFisher). Samples were stored at -80°C until RNA purification. The RNeasy Mini kit with oncolumn DNase I treatment (Qiagen) was used for RNA purification. The absence of gDNA was checked for each sample using 50 ng RNA and the *skeleton-binding protein 1* (*sbp1*) primer set (Table S1). cDNA synthesis was performed as previously described ³³.

452

453 Quantitative real-time PCR

The LightCycler 480 (Roche) was used for quantitative real-time PCR analysis using the provided LightCycler®480 software release 1.5.1.62 SP3 as previously described ³³. Briefly, cDNA template was mixed with QuantiTect SYBR Green PCR reagent (Qiagen) and 0.3 μM sense and antisense primer in a final volume of 10 μl. Reactions were incubated at 95°C for 15 min, then subjected to 40 cycles of 95°C for 15 s and 60°C for 1 min followed by a melting step (60–95°C). The specificity of each primer pair was confirmed by dissociation curve analysis after each qPCR run. Ct calculation was done using the fit points

460 analysis method provided by the software. Expression of arginyl-tRNA synthetase (PF3D7 1218600) was 461 used for normalization and Ct values obtained by analysis of 2.5 ng gDNA from Sanaria's working cell 462 bank parasites were used for calibration. Relative quantification of the 7G8 var repertoire by 2^{-ΔΔCt} 463 analysis was performed using newly designed primer sets for 7G8 (Table S1). Furthermore, primer pairs 464 targeting the housekeeping gene *fructose-bisphosphate aldolase* as well as the ring stage control *sbp1* 465 were included (Table S1). Relative expression data (RELEXP) were corrected for amplification efficiency 466 of each newly designed primer pair, which was determined by dilution of a single gDNA from 7G8 over 467 5–6 logs of concentration (Table S1). For further characterization, the full 7G8 primer set was checked 468 for cross-reactivity with NF54 gDNA ³³, but only primers targeting the partial gene Pf7G8_120024200 469 produced a specific amplicon with NF54 gDNA.

470

471 RNA and gDNA sequencing

472 RNA from cell bank parasites (aliquot B, generation 13 after thawing) was purified and processed as 473 previously described ⁶⁵. Briefly, absence of genomic DNA was checked, human globin mRNA was 474 depleted, and RNA quantity and quality were assessed with an Bioanalyzer (RIN value 8.4). A 100–500 475 bp library was prepared using the NEBNext Ultra Directional RNA Library Prep Kit for Illumina including 476 the amplification with the KAPA polymerase, and RNA sequencing on an Illumina HiSeq4000 was 477 conducted by BGI Genomics Co., Hongkong. Approximately 12.6 million clean reads were obtained for 478 pre-mosquito cell bank parasites, resulting in 6.3 million paired-end 100 bp reads.

Library construction of gDNA and paired-end 150 bp sequencing of approximately 350 bp fragments
(range: 230–430 bp) on the DNBseq platform was done by BGI Genomics Co., Hongkong with coverage
of approximately 130x (range: 129x–136x).

482

483 RNA-seq data analysis

484 After successful quality control of RNA-seq reads with FastQC v0.11.8
485 (<u>http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</u>)⁶⁶, the reads were aligned to the Pf 7G8
486 genome available from the PlasmoDB genome database release 45 or to the Pf 7G8 exon 1 *var* gene

487 sequences (Data S1)³⁷ using the RNA-seq aligner STAR v2.7.3a⁶⁷ allowing for a maximum mismatch of 488 1 (--outFilterMismatchNmax 1). Prior to read alignment, STAR was used to generate an index using the 489 genome sequence fasta file (PlasmoDB-45_Pfalciparum7G8_Genome.fasta) or the exon 1 var gene 490 sequences from Data S1. The mapped reads in Sequence Alignment/Map (SAM) format were then 491 summarized using the featureCounts ⁶⁸ function of the Rsubread R package ⁶⁹, filtering for a minimum 492 fragment length of 85 bp for paired-end reads (minFragLength=85), as was done previously ⁶⁵. While 493 the annotation file PlasmoDB-45 Pfalciparum7G8.gff was used to summarize read counts across the 494 entire Pf 7G8 genome, a simplified annotation format (SAF) file was built from var gene index files and 495 supplied as annotation file to featureCounts. 496 The R package edgeR ⁷⁰ was used to compute FPKM gene expression values using its rpkm function. The 497 gene lengths of transcripts required for FPKM normalization were extracted from the PlasmoDB-

498 45_Pfalciparum7G8_AnnotatedTranscripts.fasta file or the coding_nt.fa file (for the specific *var* gene
499 assembly mapping) by indexing it using SAMtools ⁷¹ faidx and extracting the first two columns containing
500 sequence name and length.

Raw and normalized RNA-seq data were submitted to the BioStudies ArrayExpress collection (E-MTAB-12157).

503

504 gDNA-seq data analysis, mapping and variant calling

The raw reads were trimmed, mapped and variant calls were made using the CLC Genomics Workbench version 21 for Linux. Since all subclonal lines were cloned just before sequencing by limiting dilution, only variant calls with >90% reads mapped to the alternative allele were considered. Manual inspection further reduced the number of reliable variants, as the AT-rich genome of Pf is prone to sequencing errors within repetitive regions. Results and raw data from gDNA-seq were submitted to the BioStudies ArrayExpress collection (E-MTAB-12158).

511

512 Chromatin immunoprecipitation analysis (ChIP-qPCR)

513 Chromatin immunoprecipitation was preformed essentially as described previously ⁷². Briefly, 1% 514 paraformaldehyde-crosslinked chromatin was sheared by sonication and the soluble fraction was used 515 for immunoprecipitation overnight using protein G coupled sepharose beads (GE Healthcare). 516 Antibodies used for ChIP were rabbit anti-H3 (Abcam ab1791), anti-H3K9me3 (Active Motif 39161), anti-517 H3K27ac (Abcam ab4729), and anti-H2A.Z ²⁴. Washed immune complexes were eluted and de-518 crosslinked over night at 45°C in the presence of 500 mM NaCl. After proteinase K treatment for 1h at 519 37°C, the DNA was purified from each ChIP and input sample using the MinElute kit (Qiagen 28006) and 520 analyzed by qPCR on an Applied Biosystems 7900HT fast real-time PCR system using SYBR Green PCR 521 MasterMix (ThermoFisher Scientific 4309155) and 0.9 µM sense and antisense primers (Table S1) in a 522 final volume of 10 µl. ChIP enrichment at each genomic locus was calculated as % of input DNA, and 523 histone modifications and H2A.Z were normalized relative to H3.

524

525 Data analysis and statistics

526 Categorical variables were displayed as frequencies and percentages, and continuous variables as 527 median and interquartile rage (IQR).

The differences between the two molecular methods qPCR and RNA-seq were analyzed using a Bland-Altman plot showing the agreement between two quantitative measurements. The differences between log-transformed measurements were plotted on the y-axis and the mean of the respective qPCR and RNA-seq results on the x-axis. Thus, the graph shows the deviation of the analysis results with respect to the expression level.

The expressions of *var* genes per patient were summarized in a heat map accompanied by a dendrogram of hierarchical cluster analysis applied to the expression pattern of patients. To correct for individual differences in the overall *var* transcript levels, the level for each *var* gene was normalized against total *var* transcript level in each sample. *Var* gene expressions within patient groups were summarized using the median and interquartile range (IQR). Boxplots showing the minimum, maximum, IQR, and median were used to graphically represent group expressions. Outliers, defined as values above or below the median +/- 1.5 times the IQR, are plotted outside the whiskers of the boxplot. Correlations between

individual *var* gene expressions are calculated using the Pearson correlation coefficient (PCC) with thelog-transformed measurements.

- 542
- 543 Funding

544 JH, ME, PGK, BM and AB received funding for the clinical trial and the var gene expression analysis by 545 the Federal Ministry of Education and Research in the framework of the German Centre for Infection 546 Research (DZIF) (TTU 03.702 Clinical Trial Platform and TTU 03.703 Clinical Research Group) 547 (http://www.dzif.de/). This work was supported by the DFG Research Infrastructure NGS_CC (project 548 #1016) as part of the Next Generation Sequencing Competence Network (project 423957469). NGS 549 analyses were carried out at the production site WGGC-Bonn. AB and MP received the DFG grants BA 550 5213/6-1 and PE 1618/4-1 (project #433302244), respectively, as part of the DFG Sequencing call 2019. 551 JSWM, YDH and AB were funded by the German Research Foundation (DFG) grants BA 5213/3-1 (project 552 #323759012) and BA 5213/6-1 (project #433302244). Manufacture of Sanaria® PfSPZ Vaccine, PfSPZ 553 Challenge (NF54) and PfSPZ Challenge (7G8) was funded in part by the National Institute of Allergy and 554 Infectious Diseases of the National Institutes of Health under SBIR award numbers 5R44AI058375 555 and 5R44AI055229. JCS, KAM and AD were funded by awards U19 AI110820 and R01 AI141900, from 556 the National Institute for Allergy and Infectious Diseases, National Institutes of Health. The funders had 557 no role in study design, data collection and analysis, decision to publish, or preparation of the 558 manuscript.

559

560 Acknowledgements

We thank all volunteers who participated in the trials at the Institute of Tropical Medicine in Tübingen, Germany, and the entire study team. We thank Sanaria Inc. for providing the 7G8 working cell bank parasites and the PfSPZ Challenge (7G8) used in the CHMI trials and Balázs Horváth for his help with data analysis, mapping and variant calling. The following reagents were obtained through BEI Resources, NIAID, NIH: *Plasmodium falciparum*, Strain 7G8, MRA-152, contributed by David Walliker, MRA-154, contributed by Dennis E. Kyle and MRA-926, contributed by Karen Hayton and Tom Wellems.

_		
•	61	
۰.	n /	
~	\ <i>\\\</i>	

568 References

- 569 Miller, L.H., Baruch, D.I., Marsh, K., and Doumbo, O.K. (2002). The pathogenic basis of malaria. 1.
- 570 Nature 415, 673-679. 10.1038/415673a.
- 571 2. Gardner, M.J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R.W., Carlton, J.M., Pain, A.,
- 572 Nelson, K.E., Bowman, S., et al. (2002). Genome sequence of the human malaria parasite 573 Plasmodium falciparum. Nature 419, 498-511. 10.1038/nature01097.
- 574 3. Kraemer, S.M., and Smith, J.D. (2003). Evidence for the importance of genetic structuring to the 575 structural and functional specialization of the Plasmodium falciparum var gene family. Mol
- 576 Microbiol 50, 1527-1538. 10.1046/j.1365-2958.2003.03814.x.
- 577 4. Lavstsen, T., Salanti, A., Jensen, A.T., Arnot, D.E., and Theander, T.G. (2003). Sub-grouping of 578 Plasmodium falciparum 3D7 var genes based on sequence analysis of coding and non-coding 579 regions. Malar J 2, 27. 10.1186/1475-2875-2-27.
- 580 5. Rask, T.S., Hansen, D.A., Theander, T.G., Gorm Pedersen, A., and Lavstsen, T. (2010). 581 Plasmodium falciparum erythrocyte membrane protein 1 diversity in seven genomes--divide 582 and conquer. PLoS Comput Biol 6. 10.1371/journal.pcbi.1000933.
- 583 Jensen, A.T., Magistrado, P., Sharp, S., Joergensen, L., Lavstsen, T., Chiucchiuini, A., Salanti, A., 6.
- 584 Vestergaard, L.S., Lusingu, J.P., Hermsen, R., et al. (2004). Plasmodium falciparum associated
- 585 with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes.
- 586 J Exp Med 199, 1179-1190. 10.1084/jem.20040274.
- 587 7. Bull, P.C., Berriman, M., Kyes, S., Quail, M.A., Hall, N., Kortok, M.M., Marsh, K., and Newbold,
- 588 C.I. (2005). Plasmodium falciparum variant surface antigen expression patterns during malaria.
- 589 PLoS Pathog 1, e26. 10.1371/journal.ppat.0010026.
- 590 Warimwe, G.M., Keane, T.M., Fegan, G., Musyoki, J.N., Newton, C.R., Pain, A., Berriman, M., 8.
- 591 Marsh, K., and Bull, P.C. (2009). Plasmodium falciparum var gene expression is modified by host
- 592 immunity. Proc Natl Acad Sci U S A 106, 21801-21806. 10.1073/pnas.0907590106.

593 9. Lavstsen, T., Turner, L., Saguti, F., Magistrado, P., Rask, T.S., Jespersen, J.S., Wang, C.W., Berger,

- 594S.S., Baraka, V., Marquard, A.M., et al. (2012). Plasmodium falciparum erythrocyte membrane595protein 1 domain cassettes 8 and 13 are associated with severe malaria in children. Proc Natl
- 596 Acad Sci U S A 109, E1791-1800. 10.1073/pnas.1120455109.
- 597 10. Jespersen, J.S., Wang, C.W., Mkumbaye, S.I., Minja, D.T., Petersen, B., Turner, L., Petersen, J.E.,
 598 Lusingu, J.P., Theander, T.G., and Lavstsen, T. (2016). Plasmodium falciparum var genes
 599 expressed in children with severe malaria encode CIDRalpha1 domains. EMBO Mol Med 8, 839-
- 600 850. 10.15252/emmm.201606188.
- 601 11. Kessler, A., Dankwa, S., Bernabeu, M., Harawa, V., Danziger, S.A., Duffy, F., Kampondeni, S.D.,

602 Potchen, M.J., Dambrauskas, N., Vigdorovich, V., et al. (2017). Linking EPCR-Binding PfEMP1 to

Brain Swelling in Pediatric Cerebral Malaria. Cell Host Microbe 22, 601-614 e605.
10.1016/j.chom.2017.09.009.

- Kaestli, M., Cockburn, I.A., Cortes, A., Baea, K., Rowe, J.A., and Beck, H.P. (2006). Virulence of
 malaria is associated with differential expression of Plasmodium falciparum var gene subgroups
 in a case-control study. J Infect Dis 193, 1567-1574. 10.1086/503776.
- Salanti, A., Dahlback, M., Turner, L., Nielsen, M.A., Barfod, L., Magistrado, P., Jensen, A.T.,
 Lavstsen, T., Ofori, M.F., Marsh, K., et al. (2004). Evidence for the involvement of VAR2CSA in
 pregnancy-associated malaria. J Exp Med 200, 1197-1203. 10.1084/jem.20041579.
- 611 14. Otto, T.D., Bohme, U., Sanders, M., Reid, A., Bruske, E.I., Duffy, C.W., Bull, P.C., Pearson, R.D.,
 612 Abdi, A., Dimonte, S., et al. (2018). Long read assemblies of geographically dispersed
 613 Plasmodium falciparum isolates reveal highly structured subtelomeres. Wellcome Open Res 3,
 614 52. 10.12688/wellcomeopenres.14571.1.
- 615 15. Wahlgren, M., Goel, S., and Akhouri, R.R. (2017). Variant surface antigens of Plasmodium
 616 falciparum and their roles in severe malaria. Nat Rev Microbiol 15, 479-491.
 617 10.1038/nrmicro.2017.47.
- 618 16. Deitsch, K.W., Calderwood, M.S., and Wellems, T.E. (2001). Malaria. Cooperative silencing 619 elements in var genes. Nature 412, 875-876. 10.1038/35091146.

- 620 17. Calderwood, M.S., Gannoun-Zaki, L., Wellems, T.E., and Deitsch, K.W. (2003). Plasmodium
 621 falciparum var genes are regulated by two regions with separate promoters, one upstream of
 622 the coding region and a second within the intron. J Biol Chem 278, 34125-34132.
 623 10.1074/jbc.M213065200.
- Kaestli, M., Vogel, D., Bopp, S., and Beck, H.P. (2003). Identification of nuclear
 proteins that interact differentially with Plasmodium falciparum var gene promoters. Mol
 Microbiol 48, 1593-1607. 10.1046/j.1365-2958.2003.03528.x.
- Fraschka, S.A., Henderson, R.W., and Bartfai, R. (2016). H3.3 demarcates GC-rich coding and
 subtelomeric regions and serves as potential memory mark for virulence gene expression in
 Plasmodium falciparum. Sci Rep 6, 31965. 10.1038/srep31965.
- 630 20. Duraisingh, M.T., Voss, T.S., Marty, A.J., Duffy, M.F., Good, R.T., Thompson, J.K., Freitas-Junior,
- L.H., Scherf, A., Crabb, B.S., and Cowman, A.F. (2005). Heterochromatin silencing and locus
 repositioning linked to regulation of virulence genes in Plasmodium falciparum. Cell 121, 13-24.
 10.1016/j.cell.2005.01.036.
- Ralph, S.A., Scheidig-Benatar, C., and Scherf, A. (2005). Antigenic variation in Plasmodium
 falciparum is associated with movement of var loci between subnuclear locations. Proc Natl
 Acad Sci U S A 102, 5414-5419. 10.1073/pnas.0408883102.
- Lopez-Rubio, J.J., Gontijo, A.M., Nunes, M.C., Issar, N., Hernandez Rivas, R., and Scherf, A.
 (2007). 5' flanking region of var genes nucleate histone modification patterns linked to
 phenotypic inheritance of virulence traits in malaria parasites. Mol Microbiol 66, 1296-1305.
 10.1111/j.1365-2958.2007.06009.x.
- Volz, J.C., Bartfai, R., Petter, M., Langer, C., Josling, G.A., Tsuboi, T., Schwach, F., Baum, J.,
 Rayner, J.C., Stunnenberg, H.G., et al. (2012). PfSET10, a Plasmodium falciparum
 methyltransferase, maintains the active var gene in a poised state during parasite division. Cell
 Host Microbe 11, 7-18. 10.1016/j.chom.2011.11.011.

- 645 24. Petter, M., Lee, C.C., Byrne, T.J., Boysen, K.E., Volz, J., Ralph, S.A., Cowman, A.F., Brown, G.V.,
- and Duffy, M.F. (2011). Expression of P. falciparum var genes involves exchange of the histone
 variant H2A.Z at the promoter. PLoS Pathog 7, e1001292. 10.1371/journal.ppat.1001292.
- 648 25. Petter, M., Selvarajah, S.A., Lee, C.C., Chin, W.H., Gupta, A.P., Bozdech, Z., Brown, G.V., and
- 649 Duffy, M.F. (2013). H2A.Z and H2B.Z double-variant nucleosomes define intergenic regions and
- 650 dynamically occupy var gene promoters in the malaria parasite Plasmodium falciparum. Mol
- 651 Microbiol 87, 1167-1182. 10.1111/mmi.12154.
- Jiang, L., Mu, J., Zhang, Q., Ni, T., Srinivasan, P., Rayavara, K., Yang, W., Turner, L., Lavstsen, T.,
 Theander, T.G., et al. (2013). PfSETvs methylation of histone H3K36 represses virulence genes
 in Plasmodium falciparum. Nature 499, 223-227. 10.1038/nature12361.
- 655 27. Flueck, C., Bartfai, R., Volz, J., Niederwieser, I., Salcedo-Amaya, A.M., Alako, B.T., Ehlgen, F.,
- Ralph, S.A., Cowman, A.F., Bozdech, Z., et al. (2009). Plasmodium falciparum heterochromatin
 protein 1 marks genomic loci linked to phenotypic variation of exported virulence factors. PLoS
 Pathog 5, e1000569. 10.1371/journal.ppat.1000569.
- Perez-Toledo, K., Rojas-Meza, A.P., Mancio-Silva, L., Hernandez-Cuevas, N.A., Delgadillo, D.M.,
 Vargas, M., Martinez-Calvillo, S., Scherf, A., and Hernandez-Rivas, R. (2009). Plasmodium
 falciparum heterochromatin protein 1 binds to tri-methylated histone 3 lysine 9 and is linked to
 mutually exclusive expression of var genes. Nucleic Acids Res 37, 2596-2606.
 10.1093/nar/gkp115.
- Lopez-Rubio, J.J., Mancio-Silva, L., and Scherf, A. (2009). Genome-wide analysis of
 heterochromatin associates clonally variant gene regulation with perinuclear repressive centers
 in malaria parasites. Cell Host Microbe 5, 179-190. 10.1016/j.chom.2008.12.012.
- Tang, J., Chisholm, S.A., Yeoh, L.M., Gilson, P.R., Papenfuss, A.T., Day, K.P., Petter, M., and Duffy,
 M.F. (2020). Histone modifications associated with gene expression and genome accessibility
 are dynamically enriched at Plasmodium falciparum regulatory sequences. Epigenetics
 Chromatin 13, 50. 10.1186/s13072-020-00365-5.

- 671 31. Recker, M., Buckee, C.O., Serazin, A., Kyes, S., Pinches, R., Christodoulou, Z., Springer, A.L., 672 Gupta, S., and Newbold, C.I. (2011). Antigenic variation in Plasmodium falciparum malaria 673 switching involves a highly structured pattern. PLoS Pathog 7, e1001306. 674 10.1371/journal.ppat.1001306.
- 675 32. Ukaegbu, U.E., Zhang, X., Heinberg, A.R., Wele, M., Chen, Q., and Deitsch, K.W. (2015). A Unique
 676 Virulence Gene Occupies a Principal Position in Immune Evasion by the Malaria Parasite
 677 Plasmodium falciparum. PLoS Genet 11, e1005234. 10.1371/journal.pgen.1005234.
- 678 33. Bachmann, A., Bruske, E., Krumkamp, R., Turner, L., Wichers, J.S., Petter, M., Held, J., Duffy,
- 679 M.F., Sim, B.K.L., Hoffman, S.L., et al. (2019). Controlled human malaria infection with 680 Plasmodium falciparum demonstrates impact of naturally acquired immunity on virulence gene 681 expression. PLoS Pathog 15, e1007906. 10.1371/journal.ppat.1007906.
- Wang, C.W., Hermsen, C.C., Sauerwein, R.W., Arnot, D.E., Theander, T.G., and Lavstsen, T.
 (2009). The Plasmodium falciparum var gene transcription strategy at the onset of blood stage
 infection in a human volunteer. Parasitol Int 58, 478-480. 10.1016/j.parint.2009.07.004.
- 685 35. Bachmann, A., Petter, M., Krumkamp, R., Esen, M., Held, J., Scholz, J.A., Li, T., Sim, B.K., Hoffman,
- 686 S.L., Kremsner, P.G., et al. (2016). Mosquito Passage Dramatically Changes var Gene Expression
- 687 in Controlled Human Plasmodium falciparum Infections. PLoS Pathog 12, e1005538.
 688 10.1371/journal.ppat.1005538.
- Spence, P.J., Jarra, W., Levy, P., Reid, A.J., Chappell, L., Brugat, T., Sanders, M., Berriman, M.,
 and Langhorne, J. (2013). Vector transmission regulates immune control of Plasmodium
 virulence. Nature 498, 228-231. 10.1038/nature12231.

692 37. Moser, K.A., Drabek, E.F., Dwivedi, A., Stucke, E.M., Crabtree, J., Dara, A., Shah, Z., Adams, M.,

- 693Li, T., Rodrigues, P.T., et al. (2020). Strains used in whole organism Plasmodium falciparum694vaccine trials differ in genome structure, sequence, and immunogenic potential. Genome Med
- 695 12, 6. 10.1186/s13073-019-0708-9.
- 696 38. Silva, J.C., Dwivedi, A., Moser, K.A., Sissoko, M.S., Epstein, J.E., Healy, S.A., Lyke, K.E.,
 697 Mordmuller, B., Kremsner, P.G., Duffy, P.E., et al. (2022). Plasmodium falciparum 7G8 challenge

- 698 provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa. Nat
- 699 Commun 13, 3390. 10.1038/s41467-022-30882-8.
- 700 39. Preston, M.D., Campino, S., Assefa, S.A., Echeverry, D.F., Ocholla, H., Amambua-Ngwa, A.,
- 701 Stewart, L.B., Conway, D.J., Borrmann, S., Michon, P., et al. (2014). A barcode of organellar
- 702 genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains. Nat
- 703 Commun 5, 4052. 10.1038/ncomms5052.
- Burkot, T.R., Williams, J.L., and Schneider, I. (1984). Infectivity to mosquitoes of Plasmodium
 falciparum clones grown in vitro from the same isolate. Trans R Soc Trop Med Hyg 78, 339-341.
 10.1016/0035-9203(84)90114-7.
- 41. Aurrecoechea, C., Brestelli, J., Brunk, B.P., Dommer, J., Fischer, S., Gajria, B., Gao, X., Gingle, A.,
- Grant, G., Harb, O.S., et al. (2009). PlasmoDB: a functional genomic database for malaria
 parasites. Nucleic Acids Res 37, D539-543. 10.1093/nar/gkn814.
- Otto, T.D., Assefa, S.A., Bohme, U., Sanders, M.J., Kwiatkowski, D., Pf3k, c., Berriman, M., and
 Newbold, C. (2019). Evolutionary analysis of the most polymorphic gene family in falciparum
 malaria. Wellcome Open Res 4, 193. 10.12688/wellcomeopenres.15590.1.
- Mordmuller, B., Sulyok, Z., Sulyok, M., Molnar, Z., Lalremruata, A., Calle, C.L., Bayon, P.G., Esen,
 M., Gmeiner, M., Held, J., et al. (2022). A PfSPZ vaccine immunization regimen equally
 protective against homologous and heterologous controlled human malaria infection. NPJ
 Vaccines 7, 100. 10.1038/s41541-022-00510-z.
- Sulyok, Z., Fendel, R., Eder, B., Lorenz, F.R., Kc, N., Karnahl, M., Lalremruata, A., Nguyen, T.T.,
 Held, J., Adjadi, F.A.C., et al. (2021). Heterologous protection against malaria by a simple
 chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat Commun 12, 2518.
 10.1038/s41467-021-22740-w.
- 45. Barcons-Simon, A., Cordon-Obras, C., Guizetti, J., Bryant, J.M., and Scherf, A. (2020). CRISPR
 722 Interference of a Clonally Variant GC-Rich Noncoding RNA Family Leads to General Repression
 723 of var Genes in Plasmodium falciparum. mBio 11. 10.1128/mBio.03054-19.

- 724 Salanti, A., Staalsoe, T., Lavstsen, T., Jensen, A.T., Sowa, M.P., Arnot, D.E., Hviid, L., and 46. 725 Theander, T.G. (2003). Selective upregulation of a single distinctly structured var gene in 726 chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated 727 malaria. Mol Microbiol 49, 179-191. 10.1046/j.1365-2958.2003.03570.x.
- 728 Dorin-Semblat, D., Tetard, M., Claes, A., Semblat, J.P., Dechavanne, S., Fourati, Z., Hamelin, R., 47. 729 Armand, F., Matesic, G., Nunes-Silva, S., et al. (2019). Phosphorylation of the VAR2CSA 730 extracellular region is associated with enhanced adhesive properties to the placental receptor 731 CSA. PLoS Biol 17, e3000308. 10.1371/journal.pbio.3000308.
- 732 48. Gangnard, S., Chene, A., Dechavanne, S., Srivastava, A., Avril, M., Smith, J.D., and Gamain, B.
- 733 (2019). VAR2CSA binding phenotype has ancient origin and arose before Plasmodium 734 falciparum crossed to humans: implications in placental malaria vaccine design. Sci Rep 9, 735
- 16978. 10.1038/s41598-019-53334-8.

10.1016/j.celrep.2018.02.075.

749

- 736 Rovira-Graells, N., Gupta, A.P., Planet, E., Crowley, V.M., Mok, S., Ribas de Pouplana, L., Preiser, 49. 737 P.R., Bozdech, Z., and Cortes, A. (2012). Transcriptional variation in the malaria parasite 738 Plasmodium falciparum. Genome Res 22, 925-938. 10.1101/gr.129692.111.
- 739 Milne, K., Ivens, A., Reid, A.J., Lotkowska, M.E., O'Toole, A., Sankaranarayanan, G., Munoz 50. 740 Sandoval, D., Nahrendorf, W., Regnault, C., Edwards, N.J., et al. (2021). Mapping immune 741 variation and var gene switching in naive hosts infected with Plasmodium falciparum. Elife 10. 742 10.7554/eLife.62800.
- 743 Pickford, A.K., Michel-Todo, L., Dupuy, F., Mayor, A., Alonso, P.L., Lavazec, C., and Cortes, A. 51. 744 (2021). Expression Patterns of Plasmodium falciparum Clonally Variant Genes at the Onset of a 745 Blood Infection in Malaria-Naive Humans. mBio 12, e0163621. 10.1128/mBio.01636-21.
- 746 Zanghi, G., Vembar, S.S., Baumgarten, S., Ding, S., Guizetti, J., Bryant, J.M., Mattei, D., Jensen, 52. 747 A.T.R., Renia, L., Goh, Y.S., et al. (2018). A Specific PfEMP1 Is Expressed in P. falciparum 748 Sporozoites and Plays a Role in Hepatocyte Infection. Cell Rep 22, 2951-2963.

- Gomez-Diaz, E., Yerbanga, R.S., Lefevre, T., Cohuet, A., Rowley, M.J., Ouedraogo, J.B., and
 Corces, V.G. (2017). Epigenetic regulation of Plasmodium falciparum clonally variant gene
 expression during development in Anopheles gambiae. Sci Rep 7, 40655. 10.1038/srep40655.
- 753 54. Duffy, M.F., Selvarajah, S.A., Josling, G.A., and Petter, M. (2014). Epigenetic regulation of the
- 754 Plasmodium falciparum genome. Brief Funct Genomics 13, 203-216. 10.1093/bfgp/elt047.
- 755 55. Duffy, M.F., Tang, J., Sumardy, F., Nguyen, H.H., Selvarajah, S.A., Josling, G.A., Day, K.P., Petter,
- M., and Brown, G.V. (2017). Activation and clustering of a Plasmodium falciparum var gene are
 affected by subtelomeric sequences. FEBS J 284, 237-257. 10.1111/febs.13967.
- 758 56. Frank, M., Dzikowski, R., Amulic, B., and Deitsch, K. (2007). Variable switching rates of malaria
- virulence genes are associated with chromosomal position. Mol Microbiol 64, 1486-1498.
- 760 10.1111/j.1365-2958.2007.05736.x.
- 57. Duffy, M.F., Byrne, T.J., Elliott, S.R., Wilson, D.W., Rogerson, S.J., Beeson, J.G., Noviyanti, R., and
 762 Brown, G.V. (2005). Broad analysis reveals a consistent pattern of var gene transcription in
 763 Plasmodium falciparum repeatedly selected for a defined adhesion phenotype. Mol Microbiol
 764 56, 774-788. 10.1111/j.1365-2958.2005.04577.x.
- Mordmuller, B., Supan, C., Sim, K.L., Gomez-Perez, G.P., Ospina Salazar, C.L., Held, J., Bolte, S.,
 Esen, M., Tschan, S., Joanny, F., et al. (2015). Direct venous inoculation of Plasmodium
 falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two
 centres. Malar J 14, 117. 10.1186/s12936-015-0628-0.
- 769 59. Trager, W., and Jensen, J.B. (1997). Continuous culture of Plasmodium falciparum: its impact on
 770 malaria research. Int J Parasitol 27, 989-1006. 10.1016/s0020-7519(97)00080-5.
- 60. Lambros, C., and Vanderberg, J.P. (1979). Synchronization of Plasmodium falciparum
 erythrocytic stages in culture. J Parasitol 65, 418-420.
- Rivadeneira, E.M., Wasserman, M., and Espinal, C.T. (1983). Separation and concentration of
 schizonts of Plasmodium falciparum by Percoll gradients. J Protozool 30, 367-370.
 10.1111/j.1550-7408.1983.tb02932.x.

- 776 62. Noviyanti, R., Brown, G.V., Wickham, M.E., Duffy, M.F., Cowman, A.F., and Reeder, J.C. (2001).
- 777 Multiple var gene transcripts are expressed in Plasmodium falciparum infected erythrocytes
- 778 selected for adhesion. Mol Biochem Parasitol 114, 227-237. 10.1016/s0166-6851(01)00266-3.
- 779 63. Thomas, J.A., Collins, C.R., Das, S., Hackett, F., Graindorge, A., Bell, D., Deu, E., and Blackman,
- 780 M.J. (2016). Development and Application of a Simple Plaque Assay for the Human Malaria
- 781 Parasite Plasmodium falciparum. PLoS One 11, e0157873. 10.1371/journal.pone.0157873.
- 782 64. Crabb, B.S., Cooke, B.M., Reeder, J.C., Waller, R.F., Caruana, S.R., Davern, K.M., Wickham, M.E.,
- 783 Brown, G.V., Coppel, R.L., and Cowman, A.F. (1997). Targeted gene disruption shows that knobs
- 784 enable malaria-infected red cells to cytoadhere under physiological shear stress. Cell 89, 287-
- 785 296. 10.1016/s0092-8674(00)80207-x.
- Wichers, J.S., Scholz, J.A.M., Strauss, J., Witt, S., Lill, A., Ehnold, L.I., Neupert, N., Liffner, B.,
 Luhken, R., Petter, M., et al. (2019). Dissecting the Gene Expression, Localization, Membrane
 Topology, and Function of the Plasmodium falciparum STEVOR Protein Family. mBio 10.
 10.1128/mBio.01500-19.
- Andrews, S. (2010). FastQC: A quality control tool for high throughput sequence data.
- 791 67. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and
 792 Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21.
 793 10.1093/bioinformatics/bts635.
- K. Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program
 for assigning sequence reads to genomic features. Bioinformatics 30, 923-930.
 10.1093/bioinformatics/btt656.
- Kiao, Y., Smyth, G.K., and Shi, W. (2013). The Subread aligner: fast, accurate and scalable read
 mapping by seed-and-vote. Nucleic Acids Res 41, e108. 10.1093/nar/gkt214.
- 70. Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for
 differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140.
 10.1093/bioinformatics/btp616.

802 Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., 71. 803 Durbin, R., and Genome Project Data Processing, S. (2009). The Sequence Alignment/Map 804 format and SAMtools. Bioinformatics 25, 2078-2079. 10.1093/bioinformatics/btp352. 805 Quinn, J.E., Jeninga, M.D., Limm, K., Pareek, K., Meissgeier, T., Bachmann, A., Duffy, M.F., and 72. 806 Petter, M. (2022). The Putative Bromodomain Protein PfBDP7 of the Human Malaria Parasite 807 Plasmodium Falciparum Cooperates With PfBDP1 in the Silencing of Variant Surface Antigen 808 Expression. Front Cell Dev Biol 10, 816558. 10.3389/fcell.2022.816558.

809

810 Figures

811

Table 1: Overview of volunteer characteristics infected with PfSPZ. Parasite counts were determined on the day of treatment/sampling by either thick blood smear (TBS) or qPCR.

814

815 Figure 1: Validation of 7G8-specific qPCR covering the full var gene repertoire. (A) The genomic 816 proportion of each var gene group in 7G8 parasites. (B) RNA-seq and qPCR expression data shown in a 817 Bland-Altman-Plot where the mean expression of each gene is shown on the X-axis and the ratio 818 between RNA-seg and gPCR values on the y-axis. The mean of all ratios and the confidence interval (CI) 819 of 95% are indicated by lines. Outliers are the two var1 genes (Pf7G8 020026900, Pf7G8 050037900) 820 and a B-type gene (Pf7G8_060022500), which show higher expression in RNA-seq. (C, D) The RNA 821 sample (cell bank parasites aliquot B, in vitro generation 13) analyzed via gPCR (C) or RNA-seq (D) shows 822 a nearly identical expression pattern by both analysis methods. qPCR data show gene expression of each 823 var gene relative to the normalizer arginyl-tRNA synthetase, RNA-seq data are presented in FPKM 824 (Fragments Per Kilobase of transcripts per Million mapped reads) values. Var gene names are listed on 825 the x-axis, var group affiliations are indicated in red (group A), dark red (group A, subfamily var1), blue 826 (group B), green (group C), yellow (group E, var2csa).

828 Figure 2: Var transcript profiles of pre-mosquito 7G8 cell bank parasites and of 7G8 parasites recovered 829 from infected volunteers on the first day of detectable parasitemia. (A) Heat map showing individual 830 var expression profiles for eleven volunteer samples (M08.1D, M08.2D, M16.1D, M32.1D, M32.2D, 831 M32.3P, M32.4P, M32.5P, C32.1P, C32.2P and C32.3P) taken immediately before the start of treatment 832 and six pre-mosquito cell bank parasite samples (aliquot A: *in vitro* generations 12, 15 and 24 post-thaw; 833 aliquot B: in vitro generations 6, 13 and 19 post-thaw). To correct for individual differences in the total 834 var expression levels, the expression for each var gene was normalized against total var expression in 835 each sample. Hierarchical cluster analysis confirmed that pre-mosquito cell bank parasite samples 836 differed from in vivo volunteer samples. (B, C) Gene expression of each var gene and controls relative 837 to the normalizer arginyl-tRNA synthetase expression is shown in scatter plots for the pre-mosquito cell 838 bank parasite line (B) and parasites obtained from the volunteers (C). Each point represents a value 839 observed for the pre-mosquito samples taken from two independently thawed parasite stocks after 12, 840 15 and 24 (aliquot A) or 6, 13 and 19 parasite generations (aliquot B) and for eleven volunteer samples 841 at day 11–13 after sporozoite inoculation. (D) Proportion of var gene expression by group for pre-842 mosquito cell bank parasites and parasites isolated from volunteers. (E) Comparison of the expression 843 levels between subtelomeric and centromeric var gene variants in pre-mosquito cell bank parasites and 844 parasites isolated from volunteers. Each dot represents the mean relative expression for each var gene 845 variant located in either the subtelomeric or centromeric region of the 7G8 genome. Means and 846 standard deviations are given for each group. Statistical analyses were performed using the Mann 847 Whitney U test. (F) Heat map of pairwise Pearson correlation coefficients (PCC) between expression 848 profiles illustrates the positive correlation between samples. Group affiliation of var genes is indicated 849 by the color code with A-type var genes in red, the subfamily var1 in dark red, B-type genes in blue, 850 group C genes are colored in green and the var2csa gene (group E) is shown in yellow. Control genes 851 are shown in black. Annotated pseudogenes are marked with an asterisk. H: housekeeping gene, 852 *fructose-bisphosphate aldolase*; R: ring control, *skeleton-binding protein 1 (sbp1)*.

853

854 Figure 3: Characterization of parasites expressing Pf7G8_040025600. (A) Mapping of RNA-seq reads to 855 the locus around the Pf7G8 040025600 gene in cell bank parasite aliquot B (13. in vitro generations 856 after thawing). (B) Correct down-regulation of var gene expression as the parasite matures from the 857 ring to the schizont stage (cell bank aliquot A). Var gene groups are indicated in the middle of the 858 diagrams. (C) Selection of bulk cultures and newly generated subclones on CSA. Parasites obtained from 859 BEI resources (MRA-152) and pre-mosquito cell bank parasites aliquot A (Sanaria A) and eight selected 860 subclones derived from pre-mosquito cell bank aliquot A were enriched for CSA-binding. For each cell 861 line, var gene expression is shown at three time points: (i) at the earliest time point after thawing or 862 appearance after cloning (1st), (ii) before (CSA -), and (iii) after (CSA +) CSA selection. As expected from 863 the var expression pattern, MRA-152 and the subclone A1G9 bound immediately to CSA due to the high 864 expression of var2csa in the population. After three rounds of selection, pre-mosquito cell bank 865 parasites and all other subclones were also enriched for CSA binding and var2csa expression. (D) 866 Western blots of pre-selected and CSA-selected parasites using an anti-ATS antibody (6HI) and anti-867 aldolase as loading control. The truncation of the ATS sequence of 7G8-VAR2CSA hinders recognition of 868 the protein by anti-ATS 6HI, explaining why PfEMP1 signal is lost in all parasite lines after CSA selection. 869 Similarly, MRA-152, A1G9 and A1F4 show no signal due to expression of var2csa (MRA-152, A1G9) or 870 the truncated pseudogene Pf7G8 120024200 (A1F4) before selection. Var gene names are indicated 871 and annotated pseudogenes are marked with an asterisk, var gene groups are colored according to the 872 following scheme: A in red, A-var1 in dark red, B in blue and C in green.

873

Figure 4: Epigenetic marks at the Pf7G8_040025600 and *var2csa* loci. (A) Genomic map of *var2csa* and Pf7G8_040025600 (*'varC'*) loci with surrounding open reading frames (ORFs) and transcription start sites (indicated by arrows). The positions of the respective primer pairs used for ChIP-qPCR are indicated by numbers. (B) Chromatin immunoprecipitation with anti-H3K9me3 antibody and quantification of associated gDNA regions of *var2csa* (left panel) and Pf7G8_040025600 loci (right panel) by qPCR (ChIPqPCR) in pre-mosquito cell bank parasites (aliquot A) from Sanaria (Sanaria A) and the same parasite line enriched for CSA-binding (Sanaria A CSA) (n=1). (C) Levels of gDNA marked with the

881 heterochromatin-associated H3K9me3, the activation mark H3K27ac, or the alternative histone variant 882 H2A.Z associated with active gene expression were determined by ChIP-qPCR at different regions of the 883 var2csa (left panels) and Pf7G8 040025600 (right panels) loci in subclones A2E10 (expressing 884 Pf7G8_040025600, 'varC') and A1G9 (expressing var2csa) (n=1). The boundaries of the predicted 885 heterochromatin regions are shaded in B and C. (D) The corresponding expression profiles of var genes 886 from RNA obtained in parallel with nuclei for ChIP experiments are shown as pie charts, with var2csa 887 and Pf7G8 040025600 colored as indicated and all remaining var gene variants colored grey. 888 Summarized total var gene expression is indicated for each parasite line.

889

890 Figure S1: Schematics of the MAVACHE and CVac-Tü3 study designs.

891

Figure S2: Ranking of *var* genes according to transcript levels detected in samples from malaria-naïve volunteers infected with PfSPZ 7G8. The median *var* transcript level relative to the *arginyl-tRNA synthetase* transcript level with IQR is shown for 11 volunteer samples. Group affiliation of *var* genes is indicated by the color code: A-type *var* genes in red, the subfamily *var1* in dark red, B-type genes in blue, group C genes in green, and the *var2csa* gene (group E) in yellow.

897

Figure S3: *Var* gene expression profiles of 7G8 cell bank parasites derived from Sanaria (aliquot A and B) and BEI Resources (MRA-152, MRA-926, MRA-154). (A) Heat map showing *var* expression of 7G8 parasites from Sanaria cell bank aliquots A and B and of three 7G8 aliquots deposited at BEI resources by different providers. Expression of each *var* gene is normalized to expression of *arginyl-tRNA synthetase*. (B) Pie charts showing the proportion of *var* gene expression by group for the different 7G8 lines. The names of *var* genes are indicated, and *var* gene groups are colored according to the scheme: A in red, A-*var1* in dark red, B in blue and C in green.

905

906 Figure S4: *Var* gene expression profiles of CSA-selected 7G8 cell bank parasites after cultivation for up

907 to 100 replication cycles after selection. Heat map showing the *var* expression of 7G8 cell bank parasites

908	(aliquot A) selected on CSA to express var2csa after cultivation for up to 100 parasite replications. The
909	expression of each var gene is normalized against the expression of arginyl-tRNA synthetase. The names
910	of var genes are indicated, and var gene groups are colored according to the scheme: A in red, A-var1
911	in dark red, B in blue and C in green.
912	
913	Figure S5: qPCR on gDNA from 7G8 subclones to confirm presence of each var gene variant in the
914	different genomes. Shown are raw Ct values from about 2.5 ng gDNA used as template per qPCR
915	reaction. The Ct values from the cell bank aliquot A bulk culture are marked in black for reference, and
916	a line is drawn at the mean.
917	
918	Table S1: The 7G8 var gene repertoire and the domain composition of the encoding PfEMP1 variants
919	according to the classification from Rask et al. ⁵ . Question marks indicate unknown features of the var
920	gene/PfEMP1. Gene IDs and gene type annotation according to PlasmoDB Release 58 (23. June 2022).
921	ATS: Acidic terminal segment; CIDR: Cysteine-rich interdomain region; DBL: Duffy-binding like domain;
922	NTS: N-Terminal segment; UPS: upstream sequence
923	
924	Table S2: Oligonucleotides used in this study.
925	
926	Table S3: qPCR data on 7G8 var gene expression in pre-mosquito cell bank parasites (A) and in parasites
927	from malaria-naïve volunteers (B).
928	
929	Table S4: Var gene expression in MRA-152, 7G8 pre-mosquito cell bank parasites (aliquot A) and 7G8
930	subclones before and after CSA selection.
931	
932	Table S5: Unique genomic variants of 7G8 subclones A1G9 (var2csa-expressing subclone, control) versus
933	A2G2 and A2E10 (Pf7G8_040025600-expressing subclones) determined by gDNA-seq.
934	

- 935 Table S6: ChIP-qPCR and *var* expression profiles from 7G8 pre-mosquito cell bank parasites (aliquot A)
- 936 and 7G8 subclones before and after CSA selection.
- 937
- 938 Data S1: All var exon 1 sequences used for design of the oligonucleotides and RNA-seq mapping
- 939 (coding_nt.fa) ³⁷.

Table 1: Overview of volunteer characteristics infected with PfSPZ Challenge 7G8 and parasite counts determined either by thick blood smear (TBS) or qPCR at the day of treatment/sampling.

Volunteer ID	Sex	Year of birth	Immunization	PfSPZ challenge	No. of sporozoites	Day of treatment	Parasites/µl (TBS)	Parasites/ml (qPCR)
M08.1D	m	1976	dose escalation	7G8	800	13	11	8,216
M08.2D	m	1988	dose escalation	7G8	800	12	7	717
M16.1D	m	1992	dose escalation	7G8	1,600	12	30	8,593
M32.1D	m	1989	dose escalation	7G8	3,200	11	0	3,671
M32.2D	m	1993	dose escalation	7G8	3,200	12	89	3,956
M32.3P	f	1992	placebo	7G8	3,200	10	3	3,560
M32.4P	f	1994	placebo	7G8	3,200	11	0	1,757
M32.5P	m	1991	placebo	7G8	3,200	11	0	3,666
C32.1P	f	1992	placebo	7G8	3,200	11	4	15,559
C32.2P	m	1993	placebo	7G8	3,200	10	0	8,955
C32.3P	m	1997	placebo	7G8	3,200	11	0	11,555





medRxiv preprint doi: https://doi.org/10.1101/2022.12.05.22283093; this version posted December 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Figure 3 А В ring stage (64. generation) schizonts (64. generation) ruf6 delay ult. Pf7G8_040025200 transcription factor with AP2 domain(s) Pf7G8_040025800 RIFIN Pf7G8_040025600 PfEMP1 Pf7G8 040025300 Pf7G8 040025400 Pf7G8 040025500 ribosome-recycling conserved protein, conserved protein, factor unknown function unknown function 30000 -25000 -20000 -15000 -0 20000 -25000 -10000 ò 10000 15000 -5000 5000 30000 35000 35000 RELEXP С Sanaria MRA-152 A1F4 A1F11 A1G9 A1G5 A2F10 A2G2 A2E10 A1G4 Aliquot A CSA (-) CSA (-) CSA (-) CSA (-) CSA (–) Î Ĵ Ĵ Ĵ









